title: Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy.
abstract: Radiotherapy and chemotherapeutic agents that damage DNA are the current major non-surgical means of treating cancer. However, many patients develop resistances to chemotherapy drugs in their later lives. The PI3K and Ras signaling pathways are deregulated in most cancers, so molecularly targeting PI3K-Akt or Ras-MAPK signaling sensitizes many cancer types to radiotherapy and chemotherapy, but the underlying molecular mechanisms have yet to be determined. During the multi-step processes of tumorigenesis, cancer cells gain the capability to disrupt the cell cycle checkpoint and increase the activity of CDK4/6 by disrupting the PI3K, Ras, p53, and Rb signaling circuits. Recent advances have demonstrated that PI3K-Akt-mTOR signaling controls FANCD2 and ribonucleotide reductase (RNR). FANCD2 plays an important role in the resistance of cells to DNA damage agents and the activation of DNA damage checkpoints, while RNR is critical for the completion of DNA replication and repair in response to DNA damage and replication stress. Regulation of FANCD2 and RNR suggests that cancer cells depend on PI3K-Akt-mTOR signaling for survival in response to DNA damage, indicating that the PI3K-AktmTOR pathway promotes resistance to chemotherapy and radiotherapy by enhancing DNA damage repair.
authors.affiliation: Department of Preventive Medicine, College of Military Preventive Medicine, Third Military Medical University, Chongqing, 400038, China, wangziwen8080@163.com.
authors.forename: Ziwen
authors.initials: Z
authors.lastname: Wang
authors.forename: Yujung
authors.initials: Y
authors.lastname: Huang
authors.forename: Jiqiang
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004249:DNA Damage / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects; D052236:Fanconi Anemia Complementation Group D2 Protein / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D012264:Ribonucleotide Reductases / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D052236:Fanconi Anemia Complementation Group D2 Protein; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D012264:Ribonucleotide Reductases; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human
references.citation: Nat Rev Mol Cell Biol. 2007 Apr;8(4):275-83
references.pmid: 17380161
references.citation: Nature. 2004 Nov 18;432(7015):316-23
references.pmid: 15549093
references.citation: Biochim Biophys Acta. 2004 Jun 1;1699(1-2):1-34
references.pmid: 15158709
references.citation: Leukemia. 2014 Jan;28(1):203-6
references.pmid: 23852546
references.citation: Nat Rev Cancer. 2009 Nov;9(11):785-97
references.pmid: 19851314
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: EMBO J. 1998 Dec 15;17(24):7480-9
references.pmid: 9857202
references.citation: Cell. 2012 May 25;149(5):1023-34
references.pmid: 22632967
references.citation: Genes Dev. 2010 Aug 15;24(16):1680-94
references.pmid: 20713514
references.citation: Cell. 1998 Sep 4;94(5):595-605
references.pmid: 9741624
references.citation: Annu Rev Genet. 2009;43:223-49
references.pmid: 19686080
references.citation: Int J Hematol. 2011 Apr;93(4):417-424
references.pmid: 21331524
references.citation: Leukemia. 2013 Oct;27(10):2040-2046
references.pmid: 23538752
references.citation: J Clin Oncol. 2009 May 1;27(13):2278-87
references.pmid: 19332717
references.citation: Cell. 2012 Apr 13;149(2):274-93
references.pmid: 22500797
references.citation: Curr Opin Genet Dev. 2013 Feb;23(1):53-62
references.pmid: 23317514
references.citation: Science. 2009 Dec 18;326(5960):1698-701
references.pmid: 19965384
references.citation: Cell. 2006 Sep 8;126(5):955-68
references.pmid: 16959574
references.citation: Science. 2011 Jul 15;333(6040):312-6
references.pmid: 21764741
references.citation: Nat Rev Clin Oncol. 2013 Mar;10(3):143-53
references.pmid: 23400000
references.citation: Nature. 2006 May 25;441(7092):424-30
references.pmid: 16724053
references.citation: Nat Cell Biol. 2008 Aug;10(8):935-45
references.pmid: 18604198
references.citation: Cell. 2007 Aug 10;130(3):440-55
references.pmid: 17693255
references.citation: Curr Opin Cell Biol. 2009 Apr;21(2):209-18
references.pmid: 19261457
references.citation: Cold Spring Harb Perspect Biol. 2012 Dec 01;4(12):
references.pmid: 23124837
references.citation: Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
references.pmid: 16341064
references.citation: Mol Cancer Ther. 2007 May;6(5):1552-61
references.pmid: 17513604
references.citation: Anticancer Res. 2008 Nov-Dec;28(6A):3613-9
references.pmid: 19189642
references.citation: Nat Rev Mol Cell Biol. 2013 May;14(5):297-306
references.pmid: 23594950
references.citation: Nature. 2000 Mar 2;404(6773):42-9
references.pmid: 10716435
references.citation: Mol Cell Biol. 2007 Oct;27(20):7007-17
references.pmid: 17698581
references.citation: Handb Exp Pharmacol. 2008;(181):183-219
references.pmid: 18071947
references.citation: Curr Opin Cell Biol. 2005 Dec;17(6):596-603
references.pmid: 16226444
references.citation: Cell. 2009 Mar 6;136(5):823-37
references.pmid: 19269363
references.citation: Cancer Res. 2010 Jan 1;70(1):288-98
references.pmid: 20028854
references.citation: Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3746-51
references.pmid: 11904430
references.citation: J Biol Chem. 2003 Dec 19;278(51):51372-9
references.pmid: 14551205
references.citation: Genes Dev. 2012 Jul 1;26(13):1393-408
references.pmid: 22751496
references.citation: Cancer Res. 2013 Jun 1;73(11):3393-401
references.pmid: 23633493
references.citation: Oncotarget. 2012 Oct;3(10):1068-111
references.pmid: 23085539
references.citation: Mol Cell. 2002 Sep;10(3):457-68
references.pmid: 12408816
references.citation: Clin Cancer Res. 2012 Oct 15;18(20):5816-28
references.pmid: 22932669
references.citation: J Biol Chem. 2003 Apr 18;278(16):13663-71
references.pmid: 12582162
references.citation: Cancer Lett. 2006 Sep 28;241(2):184-96
references.pmid: 16412571
references.citation: Nat Rev Cancer. 2004 May;4(5):335-48
references.pmid: 15122205
references.citation: Curr Opin Pharmacol. 2008 Aug;8(4):393-412
references.pmid: 18721898
references.citation: Cell. 2007 Jun 29;129(7):1261-74
references.pmid: 17604717
references.citation: Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
references.pmid: 21157483
references.citation: Cell. 2007 Apr 20;129(2):434
references.pmid: 17449000
references.citation: Science. 1991 Aug 23;253(5022):905-9
references.pmid: 1715094
references.citation: Acta Oncol. 2008;47(1):9-19
references.pmid: 18097777
references.citation: Science. 2005 Feb 18;307(5712):1098-101
references.pmid: 15718470
references.citation: Cell. 2006 Feb 10;124(3):471-84
references.pmid: 16469695
references.citation: Curr Opin Oncol. 2008 Jan;20(1):90-6
references.pmid: 18043262